Last mentioned: Mar 17, 2026
BofA Target Increase
Bank of America raises price target based on pharmaceutical and MedTech pipeline strength.
Institutional Rebalancing
Richard Bernstein Advisors and Rathbones Group PLC report reduced holdings in JNJ.
Fast-Track Approval
FDA approves Tecvayli-Darzalex combination for blood cancer treatment.
FDA Approval & 12-Month High
JNJ receives FDA approval for multiple myeloma combo and stock hits a yearly peak.
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
As the market enters March 2026, investors are increasingly turning to 'Dividend Kings'—companies with over 50 consecutive years of dividend increases—as a defensive hedge against lingering volatility. This briefing analyzes the top three picks for the month: Procter & Gamble, Johnson & Johnson, and Coca-Cola, highlighting their resilience and compounding potential.
Bank of America has raised its price target for Johnson & Johnson, citing robust growth in the company's pharmaceutical and MedTech pipelines. The upgrade follows a series of FDA approvals and a strategic pivot toward high-margin innovative medicine after the Kenvue spinoff.
Legend Biotech and Core Molding Technologies released their full-year 2025 financial results, highlighting a period of strategic expansion and operational resilience. While Legend Biotech continues to scale its CAR-T therapy footprint, Core Molding demonstrated steady performance in the industrial manufacturing sector.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
This page surfaces every story mentioning Johnson & Johnson across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Johnson & Johnson was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |